Skip to content

Effective dose of propofol combined with oliceridine fumarate in painless hysteroscopy

Effective dose of propofol combined with oliceridine fumarate in painless hysteroscopy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102118
Enrollment
Unknown
Registered
2025-05-08
Start date
2025-05-15
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

painless hysteroscopy

Interventions

Low dose group (group L):Oliceridine fumarate 0.5mg+ propofol
Medium dose group (M group):Oliceridine fumarate 1mg+ propofol

Sponsors

The Afffliated Shunde Hospital of Jinan University, Foshan, China
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-60 years old, BMI 18-28 kg /m^2, Mallampati grade ? or ?, no airway, head and neck conditions; 2. ASA grade I or II; 3. patients scheduled for elective hysteroscopy; 4. Patients volunteered to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Patients who refuse to participate or who are not suitable for the trial; 2. allergic to propofol or oliceridine fumarate; 3. severe cardiovascular, pulmonary, liver and kidney dysfunction or adrenal cortex dysfunction; 4. Use of alcohol, psychotropic drugs or analgesics within 24 hours before surgery; 5. epileptic seizures; 6. a history of psychological problems or mental illness; 7. history of hyperthyroidism; 8. airway hyperresponsiveness disease.

Design outcomes

Primary

MeasureTime frame
Body movement;frown;Ramsay score <5;

Secondary

MeasureTime frame
blood pressure;SPO2;

Countries

China

Contacts

Public ContactChen Jinming

The Afffliated Shunde Hospital of Jinan University, Foshan, China,

565508668@qq.com+86 131 4404 3939

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026